About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-07-31
First India Shipment of Henlius' Serplulimab
2025-07-28
CHMP Recommends EU Approval of Henlius’ Denosumab Biosimilar HLX14
2025-07-25
Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC
2025-07-25
From China’s First to Industry Benchmark | Five Years Since HANQUYOU's Global Approval, Benefiting over 260,000 Patients Worldwide
2025-07-14
Henlius’ HLX22 International Multicentre Phase 3 Head-to-Head Trial Administers First Dose to US Patient in HER2+ GC
2025-07-09
Henlius Receives Global Regulatory Approvals for Phase 2 MRCT of Its PD-L1 ADC HLX43 on NSCLC
2025-07-02
Henlius Receives New EMA GMP Certification, Accelerating European Market Entry of Two Biosimilar Candidates
2025-07-02
Henlius and HanchorBio Collaborate to Develop Novel SIRPα-Fc Fusion Protein, Expanding Tumor Immunotherapy Layout
2025-06-26
Henlius Hosts Investigator Meeting for Bridging Study of Serplulimab in Japan
1
2
3
...
7
